**09.00 – 10.30**

**Inflammation, ageing and the environment**

Room 12

**Aim:**
To highlight influences of ageing and environmental factors on risk of developing inflammatory diseases

**Outcome 1:**
To understand the effects of ageing on the immune and inflammatory settings

**Outcome 2:**
To understand the potential mechanisms by which exercise and diet influence the immune system

**09.00**

**Age-related changes in the inflammatory burden**

Prof Janet Lord, University of Birmingham, Birmingham

**09.30**

**The anti-inflammatory effects of exercise: mechanisms and implications for the prevention of common diseases**

Dr Nicolette Bishop, Loughborough University, Loughborough

**10.00**

**Diet, genes and health: towards effective personalised nutrition advice**

Prof John Mathers, Newcastle University, Newcastle-upon-Tyne

---

**09.00 – 10.30**

**British Rheumatologists in training session: vasculitis - meet the experts**

Hall 1A

**Aim:**
To provide trainees with practical teaching and advice on the management of vasculitis

**Outcome 1:**
Delegates will be able to present and discuss difficult vasculitis cases

**Outcome 2:**
Delegates will have a better understanding of clinical presentation of vasculitis

**Outcome 3:**
Delegates will be able to discuss management issues in complex vasculitis with an expert panel

**09.00**

**Meet the experts: vasculitis (trainee case presentations followed by discussion involving experts and trainees)**

Dr David Jayne, University of Cambridge, Cambridge and Prof Raashid Luqmani, University of Oxford, Oxford

---

**09.00 – 10.30**

**Statistics, damn statistics and rheumatology**

Hall 1C

**Aim:**
For rheumatology professionals to enhance their understanding of quantitative methodology including study design, statistical analysis and issues around complex data, such that they may further improve their ability to conduct research and to interpret research studies

**Outcome 1:**
To understand – (a) the basics of study design; (b) why different research designs are important; (c) how design dictates the analytical methods; (d) what are the commonly encountered designs in rheumatology

**Outcome 2:**
To learn about: (a) basic statistical research methods; (b) which tests and techniques accompany different study designs; (c) statistical methods used in rheumatology; (d) common statistical pitfalls and faux pas

**Outcome 3:**
To gain awareness of: (a) more novel approaches to enhance design and analysis (e.g. linkage of health care data); (b) issues relating to handling and interpreting more complex data (e.g. repeated measurements, missing data)

**09.00**

**An introduction to study design for professionals in rheumatology**

Dr David Culliford, University of Southampton, Southampton

**09.25**

**An introduction to statistical methods for professionals in rheumatology**

Dr Gemma Wallace, University of Oxford, Oxford

**09.50**

**An introduction to complex data for professionals in rheumatology**

Dr Kelvin Jordan, Keele University, Keele

**Session summary and questions**
### Addressing inactivity: health benefits for inflammatory and non-inflammatory patients

**Chair:** Dr Jill Halstead, University of Leeds, Leeds and Dr Simon Till, University of Sheffield, Sheffield

**Aim:** To provide clinicians and therapists with an overview of the issues surrounding inactivity and sedentary lifestyle and provide practical knowledge of exercise prescription for arthritis patients

**Outcome 1:** Delegates will be able to understand the impact of inactivity upon cardio-respiratory fitness and the onset and development of co-morbidities

**Outcome 2:** Delegates will have an understanding of motivational interviewing techniques to engender lifestyle change

**Outcome 3:** Delegates will have a better understanding of the barriers to physical activity and exercise prescription for arthritis patients

**09.00**

**Physical activity and sedentary behaviour: health implications for the rheumatology multidisciplinary team**

Prof Stuart Biddle, Loughborough University, Loughborough

**09.30**

**Understanding behaviour change: the role of motivational interviewing**

Dr Jeff Breckon, Sheffield Hallam University, Sheffield

**10.00**

**Exercise prescription: a practical guide to prescribing physical activity for patients with arthritis**

Dr Eleanor Tillett, University College London, London

### Imaging pathogenesis oral abstracts

**Chairs:** Prof Philip Conaghan, Chapel Allerton Hospital, Leeds and Dr Pamela Peterson, Newcastle University, Newcastle-upon-Tyne

**09.00**

**Ultrasound measures of synovitis reflects histological synovial inflammation in early arthritis patients**

Dr Nora Ng, Queen Mary University of London, London

**09.15**

**Can we replace temporal artery biopsy with cranial ultrasound for the diagnosis of giant cell arteritis? A retrospective cohort study of the diagnostic utility of ultrasound in routine clinical practice**

Dr Adam Croft, University of Birmingham, Birmingham

**09.30**

**The case is cracked: identification of a new suspect in the initiation of osteoarthritis**

Prof Alan Boyde, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London

**09.45**

**Cardiac MRI abnormalities are associated with arrhythogenic events in systemic sclerosis: evidence for the use of the implantable cardiac defibrillator as primary prevention of sudden cardiac death**

Dr Matthew Webber, Royal Free Hospital, London

**10.00**

**Longitudinal assessment of scleroderma skin by optical coherence tomography: preliminary validation of sensitivity to change over-time**

Dr Giuseppina Abignano, University of Leeds and Leeds Teaching Hospitals NHS Trust, Leeds

**10.15**

**Imaging atherosclerotic plaque inflammation in rheumatoid arthritis: methodology and initial findings in a single centre cohort study**

Dr Sarah Skeoch, University of Manchester, Manchester
### Nurse-led care: setup, issues and opportunities

**Chairs:** Ms Jill Firth, Pennine MSK Partnership Ltd, Oldham and Dr Sarah Ryan, University Hospital of North Staffordshire, Stoke-on-Trent

**Aim:** To provide an overview of nurse-led care (NLC) setup and how its benefits can be maximised

**Outcome 1:** Delegates will have an increased awareness of how NLC service is set up, practical issues, quality assurance and auditing

**Outcome 2:** Delegates will have an example of evidence-based NLC service for newly diagnosed patients from Denmark

**Outcome 3:** Delegates will have a greater understanding of the evidence and the opportunities for improving NLC in rheumatology

**09.00** Nurse-led care in rheumatology: service setup, practical issues, quality assurance and auditing
Mrs Patricia Cornell, Poole Hospital NHS Foundation Trust, Poole

**09.30** Nurse-led screening for cardiovascular risk in rheumatoid arthritis and other types of inflammatory arthritis. Experience from Denmark
Dr Jette Primdahl, King Christian X’s Hospital for Rheumatic Diseases, Graasten, Denmark

**10.00** Nurse-led care: is the future orange? Using the evidence to maximise the effects
Dr Mwidimi Ndosi, Chapel Allerton Hospital, Leeds

### Adolescent and young adult special interest group

**Chairs:** Dr Flora McErlane, Great North Children’s Hospital, Newcastle-upon-Tyne and Dr Alison Jordan, Queen Elizabeth Hospital Birmingham, Birmingham

**Aim:** To promote high quality, young person friendly health services, engaging and informing stakeholders across paediatric, adolescent, and adult groups

**Outcome 1:** To promote and improve understanding of the You’re Welcome criteria: a Department of Health initiative to improve health outcomes in young people

**Outcome 2:** To understand the challenges of ensuring continuous, high quality healthcare for adolescents and young adults and explore how young people friendly services have been achieved in different centres across the UK

**Outcome 3:** To explore long-term health outcomes in young people with juvenile idiopathic arthritis (JIA), with particular reference to cardiovascular morbidity and mortality

**09.00** Developing young people friendly musculoskeletal services: the Sheffield experience
Dr Rachel Tattersall, Sheffield Teaching Hospitals NHS Foundation Trust and Sheffield Children’s Hospital, Sheffield

**09.30** Integrating research into rheumatology services for young people
Mrs Helen Hanson, University of Newcastle, Newcastle-upon-Tyne

**10.00** Cardiovascular risk in adults with juvenile idiopathic arthritis
Dr Elizabeth Coulson, University of Newcastle, Newcastle-upon-Tyne

### Scleroderma special interest group

**Chair:** Prof Chris Denton, Royal Free Hospital, London

**Aim:** To update on management of renal scleroderma and pulmonary hypertension in scleroderma

**Outcome 1:** Understand the best current management of scleroderma renal crisis

**Outcome 2:** Review latest developments in screening and treating pulmonary hypertension in scleroderma

**Outcome 3:** Consider novel approaches to therapy: new agents and intensive immunosuppression and relevance to renal crisis and pulmonary hypertension

**09.00** Management of scleroderma associated pulmonary hypertension
Dr David Kiely, Sheffield University, Sheffield

**09.30** Management of scleroderma renal crisis
Dr Voon Ong, Royal Free Hospital, London

**10.00** Consider novel approaches to therapy: new agents and intensive immunosuppression
Prof Jacob van Laar, University Medical Centre, Utrecht, the Netherlands
10.40 – 11.10

**How to get your abstract published**

*Hall 1A*

**Aim:** To provide delegates with the tools to submit a quality abstract submission

**Outcome 1:** Delegates will understand the key issues surrounding a quality abstract submission

**Outcome 2:** Delegates will be able to critically analyse an abstract submission with a view to improving the quality

**Outcome 3:** Delegates will be able to re-formulate an abstract to make a quality submission

10.40

**How to get your abstract published**

Dr David Coady, Sunderland General Hospital, Sunderland

10.30 – 11.30

**Exhibition | Tea and coffee**

Please see exhibition floor plan on page 89 for catering points.

10.30 – 11.30

**Poster viewing categories**

*Exhibition hall*

- 232–240 Basic science
- 241–242 Biology of bone cartilage and connective tissue
- 243 Cell receptor-ligand interaction signalling activation and apoptosis
- 244 Cytokines and inflammatory mediators
- 245–262 Education
- 263–266 Genetics
- 267–272 Imaging
- 273–278 Metabolic and crystal arthropathies
- 279–297 Paediatric and adolescent rheumatology
- 298–303 Pain
- 304–320 Scleroderma and related disorders
- 321–331 Systemic lupus erythematosus and antiphospholipid syndrome
- 332–343 Vasculitis
Day three of our ever popular poster tours. Small groups are led by experts around carefully selected posters for a Q&A with the poster presenters. Each expert will lead delegates through a group of approximately 10 posters, allowing presenters to share their research in an interactive format.
Sign up for the poster tours at the poster desk in the **exhibition hall**. Tours are limited to 15 participants.

<table>
<thead>
<tr>
<th>10.30 – 11.30</th>
<th><strong>Adolescent and paediatric rheumatology poster tour</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>10.30 – 11.30</td>
<td><strong>Exhibition hall</strong></td>
</tr>
</tbody>
</table>

### Adolescent and paediatric rheumatology poster tour

**Poster tour leader:** Dr Helen Foster, Newcastle University, Newcastle-upon-Tyne

<table>
<thead>
<tr>
<th>Poster</th>
<th>Title</th>
<th>Speaker</th>
<th>Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>280</td>
<td>Musculoskeletal anomalies in a national cohort of children and adolescents with trisomy 21</td>
<td>Dr Charlene Foley, Our Lady’s Children’s Hospital, Dublin, Ireland</td>
<td></td>
</tr>
<tr>
<td>282</td>
<td>Safety and effectiveness of adalimumab in children with polyarticular juvenile idiopathic arthritis aged 2 to 4 years weighing kg</td>
<td>Dr Hartmut Kupper, AbbVie Deutschland GMBH &amp; Co., Ludwigshafen, Germany</td>
<td></td>
</tr>
<tr>
<td>284</td>
<td>Enthesitis related arthritis and two distinct patterns of disease: clinical characteristics and outcomes in a cohort of 109 patients</td>
<td>Dr Corinne Fisher, University College London and Great Ormond Street Hospital, London</td>
<td></td>
</tr>
<tr>
<td>289</td>
<td>Assessment of radiographic progression in patients with systemic juvenile idiopathic arthritis treated with tocilizumab: 2-year results from the tender trial</td>
<td>Assoc Prof Dr Angelo Ravelli, Paediatric Rheumatology International Trials Organisation (PRINTO), Genoa, Italy</td>
<td></td>
</tr>
<tr>
<td>290</td>
<td>Being ‘as normal as possible’: how young people value the risks and benefits of treatment</td>
<td>Ms Ruth Hart, Newcastle University, Newcastle-upon-Tyne</td>
<td></td>
</tr>
<tr>
<td>293</td>
<td>Use of non-etanercept biologics in children with juvenile idiopathic arthritis: results from the biologics for children with rheumatic diseases study</td>
<td>Mrs Lianne Kearsley-Fleet, University of Manchester, Manchester</td>
<td></td>
</tr>
<tr>
<td>295</td>
<td>Paradoxically elevated levels of tumour necrosis factor in patients with juvenile idiopathic arthritis on etanercept</td>
<td>Dr Corinne Fisher, University College London and Great Ormond Street Hospital, London</td>
<td></td>
</tr>
<tr>
<td>296</td>
<td>The relationship between benign joint hypermobility syndrome and motor difficulties in children</td>
<td>Mrs Victoria Easton, Norfolk and Norwich University Hospital, Norwich</td>
<td></td>
</tr>
</tbody>
</table>
Scleroderma poster tour

Poster tour leader: Dr Marina Anderson, University of Liverpool, Liverpool

304 Modulating the fibrotic effects of fibrocytes from scleroderma patients
Dr Sarah Trinder, University College London, London

305 Anticentromere antibody disease duration and history of surgical debridements predict calcinosis in patients with systemic sclerosis
Dr Joanne Manning, Salford Royal NHS Foundation Trust, Salford

306 IL6 trans-signalling mediates M2 macrophage polarisation and fibrotic response in SSC
Miss Rebecca Alade, University College London, London

307 Long term survival in systemic sclerosis patients: development of a predictive model
Dr Svetlana Nihtyanova, University College London, London

309 Investigating the role of MRTF-A in systemic sclerosis
Dr Richard Stratton, Royal Free Hospital, London

311 Multiplex cytokine analysis of dermal interstitial blister fluid in systemic sclerosis defines potential pathogenic pathways and differentiates clinical subsets
Dr Kristina Clark, University College London, London

313 Nail-fold capillaroscopy abnormalities in an unselected cohort of patients with Raynaud’s phenomenon confirms significant association of antibody positivity and SSC pattern: experience from a single tertiary centre
Dr Lesley-Anne Bissell, University of Leeds, Leeds

316 Retrospective review of patients with systemic sclerosis on home parenteral nutrition
Dr Elizabeth Harrison, University of Manchester, Manchester

320 The prognosis of scleroderma renal crisis in rna-polymerase iii antibody (ARA) positive compared to ARA negative patients
Dr Bernadette Lynch, University College London, London
### Poster tours

**Vasculitis poster tour**

Poster tour leader: Prof David G. I. Scott, Norfolk and Norwich University Hospital, Norwich

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Presenter</th>
</tr>
</thead>
<tbody>
<tr>
<td>332</td>
<td>Increased circulating TH17 and NKT cells in takayasu’s arteritis</td>
<td>Dr Durga Misra, Sanjay Gandhi Postgraduate Institute of Medical Sciences (SGPGIMS), Lucknow, India</td>
</tr>
<tr>
<td>333</td>
<td>Long-term efficacy and safety of rituximab in anca associated vasculitis: results from a UK tertiary referral centre</td>
<td>Dr Fiona Pearce, Queen’s Medical Centre, Nottingham</td>
</tr>
<tr>
<td>334</td>
<td>United Kingdom and Ireland vasculitis registry (UKIVAS): cross-sectional data on the first 556 patients</td>
<td>Dr Jan Sznajd, University of Oxford, Oxford</td>
</tr>
<tr>
<td>335</td>
<td>Factors determining early damage in takayasu’s arteritis</td>
<td>Dr Durga Misra, Sanjay Gandhi Postgraduate Institute of Medical Sciences (SGPGIMS), Lucknow, India</td>
</tr>
<tr>
<td>337</td>
<td>Standardisation of disease assessment in systemic vasculitis: use of a novel web-based software training application</td>
<td>Dr Jan Sznajd, University of Oxford, Oxford</td>
</tr>
<tr>
<td>338</td>
<td>Hla-dpb alleles and granulomatosis with polyangiitis (Wegener’s)</td>
<td>Dr Richard Watts, University of East Anglia, Norwich</td>
</tr>
<tr>
<td>342</td>
<td>Is plasma viscosity an acceptable substitute for erythrocyte sedimentation rate for the diagnosis of giant cell arteritis?</td>
<td>Dr Sarah Mackie, University of Leeds, Leeds</td>
</tr>
<tr>
<td>343</td>
<td>Serum vascular endothelial growth factor is selectively upregulated in patients with biopsy-proven giant cell arteritis</td>
<td>Mr Julien Morlet, Oxford University, Oxford</td>
</tr>
</tbody>
</table>
### Basic science oral abstracts

**Chairs:** Prof Justin Mason, Imperial College London, London and Prof Ian Clark, University of East Anglia, Norwich

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Author, Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>11.30</td>
<td>Metabolic profiles of synovial fibroblasts: implications for disease processes in inflammatory arthritis</td>
<td>Dr Sabrina Kapoor, University of Birmingham, Birmingham</td>
</tr>
<tr>
<td>11.45</td>
<td>Presence of synovial lymphocyte aggregates correlates with a more severe clinical phenotype in patients with early inflammatory arthritis</td>
<td>Dr Maria Di Cicco, Queen Mary University of London, London</td>
</tr>
<tr>
<td>12.00</td>
<td>Hydroxychloroquine is cardioprotective in neonatal rat cardiomyocytes exposed to simulated myocardial ischaemic/reperfusion injury – an effect mediated through ERK phosphorylation</td>
<td>Miss Lauren Bourke, University College London, London</td>
</tr>
<tr>
<td>12.15</td>
<td>Proteinase-activated receptor-2 critically influences osteophyte formation in experimental osteoarthritis</td>
<td>Dr Carmen Huesa, University of the West of Scotland, Paisley</td>
</tr>
<tr>
<td>12.30</td>
<td>SLE susceptibility gene ube2l3 polymorphism controls sensitivity of NF-kB to TNF and CD40 in vivo</td>
<td>Dr Myles Lewis, King’s College London, London</td>
</tr>
<tr>
<td>12.45</td>
<td>Abnormally differentiating keratinocytes in the epidermis of systemic sclerosis patients show enhanced secretion of CCN2 and S100a9</td>
<td>Dr Richard Stratton, Royal Free Hospital, London</td>
</tr>
</tbody>
</table>

### British Rheumatologists in training session: clinical teaching on systemic sclerosis

**Chairs:** Dr Elena Nikiphorou, University College London, London and Dr Sonia Panchal, University Hospitals of Leicester NHS Trust, Leicester

**Aim:** To provide trainees with up-to-date clinical teaching on systemic sclerosis

**Outcome 1:** Delegates will have a better understanding of the pathophysiology of systemic sclerosis

**Outcome 2:** Delegates will learn the current evidence base for the treatment of systemic sclerosis

**Outcome 3:** Delegates will have a better understanding of the management of systemic sclerosis outside of the current evidence base

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Author, Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>11.30</td>
<td>Scleroderma: current clinical challenges and case-based discussion</td>
<td>Prof Chris Denton, Royal Free Hospital, London and Prof Ariane Herrick, University of Manchester, Manchester</td>
</tr>
</tbody>
</table>
### The need and approaches to stratified medicine in inflammatory arthritis

**Chair:** Dr Maya Buch, University of Leeds, Leeds

**Aim:** To inform the audience in a topical clinical science subject relevant clinical practice

| Outcome 1: | Enhance understanding of the need to stratified medicine in inflammatory arthritis |
| Outcome 2: | Enhance knowledge of potential approaches to stratified medicine |
| Outcome 3: | Improve patient care through stratified medicine approaches |

#### 11.30 – 13.00

| 11.30 | The need for stratified medicine in inflammatory arthritis |
| Prof John Isaacs, University of Newcastle, Newcastle-upon-Tyne |
| 11.50 | Genomic approaches to stratified medicine, what have we learnt? |
| Prof Anne Barton, University of Manchester, Manchester |
| 12.10 | Metabolic fingerprinting of disease activity and response to therapy |
| Dr Stephen Young, University of Birmingham, Birmingham |
| 12.30 | From the disease tissue to the whole patient: the role of pathobiology in patient stratification |
| Prof Costantino Pitzalis, Barts and the London School of Medicine and Dentistry, London |

### Droitwich lecture and prize session

**Chair:** Mr Robert Field, President of British Health Professionals in Rheumatology (BHPR)

The Droitwich lecture marks the highlight of the BHPR programme, incorporating the presentation of the prestigious Droitwich lecturer session and the BHPR award presentations - an opportunity for inspiring allied health professionals to share their work.

**11.30**

**Remodelling osteoarthritis care: maximising the impact of best evidence**

Prof Krysia Dziedzic, Arthritis Research UK, Professor of Musculoskeletal Therapies, Keele University and NICE fellow

**British Health Professionals in Rheumatology awards ceremony**

**12.15**

### Paediatric and adolescent rheumatology oral abstracts

** Chairs:** Dr Jacqui Clinch, University Hospitals Bristol, Bristol and Dr Helen Foster, Newcastle University, Newcastle-upon-Tyne

#### 11.30 – 13.00

| 11.30 | Trends in paediatric rheumatology referral times and disease activity indices over a ten-year period among children with juvenile idiopathic arthritis (JIA): results from the childhood arthritis prospective study |
| Dr Flora McErlane, Great North Children’s Hospital, Newcastle-upon-Tyne |
| 11.45 | Early growth of lean, rather than fat mass, predicts bone size, mineralisation and density in childhood: findings from the Southampton women’s survey |
| Dr Zoe Cole, University of Southampton, Southampton |
| 12.00 | Growth in children and adolescents with juvenile idiopathic arthritis after 2 years of treatment with etanercept: results from the British Society for Paediatric and Adolescent Rheumatology (BSPAR) etanercept cohort study |
| Mrs Lianne Kearsley-Fleet, University of Manchester, Manchester |
| 12.15 | Efficacy and safety of adalimumab in pediatric patients with enthesitis related arthritis |
| Aileen Pangan, AbbVie Inc., Chicago, United States |
| 12.45 | Predictors of pain reporting over time in juvenile idiopathic arthritis using trajectory analysis: results from the childhood arthritis prospective study |
| Dr Amir Rashid, University of Manchester, Manchester |
### Lung disease in rheumatoid arthritis special interest group

**Room 11B**

**Chair:** Dr Bridget Griffiths, Freeman Hospital, Newcastle-upon-Tyne

**Aim:** To review the data on survival of patients with (a) interstitial lung disease in rheumatoid arthritis (BRILL) (b) bronchiectasis in rheumatoid arthritis (BROAD), and to discuss the developing program for developing drug trials in the management of these conditions

**Outcome 1:** To update delegates on the progress made to date within the BRILL and BROAD networks relating to patient outcomes

**Outcome 2:** To involve delegates in the assessment of the most relevant clinical questions we now need to address in the management of these disorders

**Outcome 3:** To define the structure of drug trials for both interstitial lung disease and bronchiectasis in patients with rheumatoid arthritis

11.30  **What have we learned from our clinical networks on lung disease in rheumatoid arthritis?**
Dr Elizabeth Perry, South West Deanery

12.15  **What clinical questions are rheumatologists now asking about the management of lung disease in rheumatoid arthritis?**
Dr David Hutchinson, Royal Cornwall Hospitals, Truro

12.45  **What studies do we need to do next to answer these issues?**
Dr Clive Kelly, Queen Elizabeth Hospital, Gateshead

### Soft tissue rheumatism and sports medicine special interest group

**Room 4**

**Chair:** Dr Tim Jones, the Defence Medical Rehabilitation Centre, Headley Court, Epsom

**Aim:** To illustrate how rheumatological practice is altered in young, old and female active populations

**Outcome 1:** To highlight unusual or important conditions that present to a rheumatology clinic in specific active populations

**Outcome 2:** To highlight how important medical conditions may present in atypical ways in active populations

**Outcome 3:** To discuss how exercise should be modified in different active populations

11.30  **Unusual cases presenting to a rheumatology clinic from an active young population**
Dr Rhodri Phillip, the Defence Medical Rehabilitation Centre, Headley Court, Epsom

12.00  **Rheumatology for an active ageing population**
Dr Aisling Coy, Salisbury District Hospital, Salisbury

12.30  **Rheumatology in an active female population**
Dr Julia Newton, Oxford University Hospitals, Oxford
11.30 – 13.00

**Room 11A**

**British Society for Rheumatology education special interest group**

Chairs: Prof Andrew Hassell, Keele University, Keele and Dr Lesley Kay, Musculoskeletal Services Directorate, Newcastle-upon-Tyne

**Aim:**
To promote the development of education of rheumatology patients and of health professionals active in the area of rheumatology. To develop networks of rheumatology educators. To develop collaborative research and development projects within the realm of rheumatology education

**Outcome 1:**
Using the results of a national study, participants will evaluate the learning needs of rheumatology nurses in the context of treatment counselling

**Outcome 2:**
Participants will identify ways of including effective peer supported learning in a curriculum.

**Outcome 3:**
Participants will receive an update on the work of Arthritis Research UK (ARUK) in this area, including discussion of the Educators’ conference

11.30
Rheumatology nurses counselling patients re methotrexate: an investigation of educational needs
Ms Sandra Robinson, North Tyneside Hospital, North Shields

11.50
**Peer-supported learning in undergraduate medical musculoskeletal modules**
Dr Kelsey Watt, NHS Lothian

12.10
**The impact of educational resources on adult and paediatric musculoskeletal examination - a UK survey**
Dr Ken Baker, Newcastle University, Newcastle-upon-Tyne

12.30
**Update on educational activities and opportunities in Arthritis Research UK**
Dr Inam Haq and Dr Tom Margham, Arthritis Research UK

12.50
Discussion

13.00 – 14.15

**Exhibition | Lunch**

Please see exhibition floor plan on page 89 for catering points.

13.00 – 14.00

**British Health Professionals in Rheumatology members’ meeting**

You are invited to the

**BHPR Members’ Meeting**

Room 3
Thursday 1 May at 13.00 – 14.00

Lunch bags will be provided

The first members’ meeting follows on from the Droitwich Lecture and prize giving session. The agenda will focus on topical issues such as the national audit, commissioning and regional development.

The BHPR regional representatives for the various professions will be there to meet you. Come along and find out more, bring a colleague and get involved.

For more information visit our website: [www.rheumatology.org.uk/bhpr/meetings](http://www.rheumatology.org.uk/bhpr/meetings)
13.00 – 15.45

**British Rheumatologists in Training Annual General Meeting**

**Hall 1A**

**13.00 – 14.15**

**The Standards, Guidelines and Audit Working Group (SAGWG): open forum**

**Welcome and introduction**
Dr Jo Ledingham, Chair of the Standards, Guidelines and Audit Working Group

**SAGWG update, including call for new guideline topics**
Dr Jo Ledingham, Chair of the Standards, Guidelines and Audit Working Group

**National audits**
Gout: Dr Ed Roddy, Clinical Senior Lecturer in Rheumatology and Honorary Consultant Rheumatologist, Keele University, Keele
HQIP: Catherine Burns, Project Director

**14.15 – 15.45**

**Advances in innate immunity and rheumatology**

**Room 12**

**Chair:** Dr Kim Midwood, University of Oxford, Oxford

**Aim:**
To provide an update on emerging data that reveal new ways in which innate inflammation mediates joint destruction in rheumatoid arthritis

**Outcome 1:**
Delegates will gain an understanding of the biology of microRNAs, as well as an appreciation of how these fascinating, multifunctional molecules sustain chronic inflammation in the rheumatoid arthritis symposium

**Outcome 2:**
Delegates will learn more about a newly identified subset of B cells that exhibit the surprising ability to suppress inflammation, as well as learning how these cells become dysregulated in rheumatoid arthritis

**Outcome 3:**
Delegates will gain an understanding of the complexities of innate immune sensing and the mechanisms by which receptors designed to detect pathogens and tissue injury drive inflammation in immune diseases

**14.15**

**The role of microRNAs in the regulation of the immune response in arthritis**
Dr Mariola Kurowska-Stolarska, University of Glasgow, Glasgow

**14.45**

**Regulatory B cells in health and arthritis**
Dr Mohini Gray, University of Edinburgh, Edinburgh

**15.15**

**Innate immune sensing: toll like receptors and beyond**
Prof Kathy Triantafilou, Cardiff Institute of Infection & Immunity, Cardiff

**14.15 – 15.45**

**British Rheumatologists in Training session: adding value to your CV**

**Hall 1A**

**Chair:** Dr Elena Nikiphorou, University College London, London and Dr Sonia Panchal, University Hospitals of Leicester NHS Trust, Leicester

**Aim:**
To inform trainees on new NHS reforms, the impact on rheumatology and ways of adding value to their CV

**Outcome 1:**
Delegates will have a better understanding of new NHS reforms and their impact on rheumatology, learn about new initiatives e.g. Best Practice Tariffs

**Outcome 2:**
Delegates will have an opportunity to present their experience from interesting OOPEs and inspire others

**Outcome 3:**
Delegates will learn from others’ experiences and ways of adding value and improving their CV

**14.15**

**Gaining knowledge and experience of the healthcare environment: outside the curriculum!**
Dr Gavin Clunie, Ipswich Hospital, Ipswich

**14.45**

**Adding value (how can a District General Hospital add value?)**
Dr Stuart Kyle, North Devon District Hospital, Barnstaple

**15.15**

**Navigating the new NHS**
Dr Andrew Östör, Addenbrooke’s Hospital, Cambridge
### Adolescent and young adult rheumatology update

Chair: Dr Liza McCann, Alder Hey Children’s Hospital, Liverpool

**Aim:** Update on dermatological manifestations of childhood onset rheumatological conditions and the progression/prognosis in young adulthood

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>14.15</td>
<td>Dermatological manifestations of childhood and adolescent onset rheumatological diseases: recognition, treatment and prognosis into young adulthood</td>
</tr>
<tr>
<td>14.45</td>
<td>Adolescent onset spondyloarthropathies and enthesitis related arthritis: current understanding of pathophysiology, management and prognosis as patients enter early adulthood</td>
</tr>
<tr>
<td>15.15</td>
<td>Childhood onset osteoporosis: pathophysiology and management as they enter adolescent and young adult life</td>
</tr>
</tbody>
</table>

**Outcome 1:** Delegates will have enhanced their understanding of adolescent onset spondyloarthropathies and their progress and management into young adult life

**Outcome 2:** Delegates will have enhanced their understanding of pathophysiology and management of bone disorders in childhood as they transition into young adult life

### Innovative models of care

Chair: Dr Melanie Holden, Keele University, Keele and Dr Mwidimi Ndosi, Chapel Allerton Hospital, Leeds

**Aim:** To provide clinicians with an overview of innovative models of care, which can improve clinical management

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>14.15</td>
<td>PhysioDirect telephone assessment and treatment services: results of a randomised controlled trial</td>
</tr>
<tr>
<td>14.45</td>
<td>Patient access to online electronic medical records: advantages, disadvantages and preconditions according to care providers</td>
</tr>
<tr>
<td>15.15</td>
<td>Print away my arthritis foot pain: next generation 3D printed orthotics</td>
</tr>
</tbody>
</table>
### Connective tissue disease (CTD) oral abstracts

**Chairs:** Dr Hector Chinoy, University of Manchester, Manchester and Dr Benjamin Rhodes, University Hospitals Birmingham NHS Foundation Trust, Birmingham

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Presenter</th>
<th>Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>14.15</td>
<td>Prevalence of autoantibodies to HMGCR in myositis patients</td>
<td>Dr Zoe Betteridge</td>
<td>University of Bath, Bath</td>
</tr>
<tr>
<td>14.30</td>
<td>Microarray transcriptional profiling of limited cutaneous systemic sclerosis identifies a vascular gene expression signature</td>
<td>Dr Emma Derrett-Smith</td>
<td>University College London, London</td>
</tr>
<tr>
<td>14.45</td>
<td>Autoantibody in juvenile dermatomyositis reflects disease activity: results of a pilot study</td>
<td>Dr Sarah Tansley</td>
<td>Royal National Hospital of Rheumatic Diseases, Bath</td>
</tr>
<tr>
<td>15.00</td>
<td>Long-term outcomes of children born to mothers with systemic lupus erythematosus exposed to hydroxychloroquine in pregnancy</td>
<td>Dr Mary Gayed</td>
<td>University of Birmingham, Birmingham</td>
</tr>
<tr>
<td>15.15</td>
<td>The cellular effects of anti-factor XA antibodies isolated from patients with antiphospholipid syndrome are inhibited by factor XA inhibitors, hydroxychloroquine and fluvastatin</td>
<td>Dr Bahar Artim-Esen</td>
<td>Istanbul University, Istanbul, Turkey</td>
</tr>
<tr>
<td>15.30</td>
<td>Extra-corporeal membrane oxygenation and diffuse alveolar haemorrhage in systemic vasculitides: a single centre case series and analysis of the the Extracorporeal Life Support Organization (ELSO) database database</td>
<td>Dr Chai-Ying Ling</td>
<td>Guy’s &amp; St Thomas’ Hospital, London</td>
</tr>
</tbody>
</table>

### MS health of the ethnic minority special interest group

**Chairs:** Dr Ash Samanta and Dr Arumugam Moorthy, University Hospitals of Leicester NHS Trust, Leicester

**Aim:** To provide an overview of the issues relating to ethnicity and rheumatic diseases

**Outcome 1:** Delegates will have a better understanding of the relevance of ethnic variations in rheumatic diseases

**Outcome 2:** Delegates will be able to improve their management of ethnic minority patients with inflammatory arthritis

**Outcome 3:** Delegates will be able to identify ways of enhancing patient education and empowerment for ethnic groups

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Presenter</th>
<th>Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>14.15</td>
<td>Epidemiology of rheumatic diseases in different ethnic groups</td>
<td>Prof Deborah Symmonds</td>
<td>University of Manchester, Manchester</td>
</tr>
<tr>
<td>14.45</td>
<td>Challenges in managing ethnic minority patients with rheumatic diseases</td>
<td>Dr Arumugam Moorthy</td>
<td>University Hospitals of Leicester NHS Trust, Leicester</td>
</tr>
<tr>
<td>15.15</td>
<td>Commissioning musculoskeletal service: influence of ethnicity</td>
<td>Prof Peter Kay</td>
<td>Wrightington Hospital, Wigan</td>
</tr>
</tbody>
</table>
### Foot and ankle special interest group

**Chair:** Dr Catherine Bowen, University of Southampton, Southampton

**Aim:** To discuss the clinical importance of the advent of biological therapies to manage rheumatoid arthritis relative to foot pathology and the implementation of new approaches to foot healthcare/management

**Outcome 1:** Delegates will review rheumatoid arthritis foot pathologies and consider the current evidence that investigates the primary aetiology as mechanical, inflammatory or both

**Outcome 2:** Delegates will consider whether biologic therapies have a significant impact on the management of rheumatoid arthritis foot pathology

**Outcome 3:** Delegates will discuss investigation of the role of specialist podiatry foot-care alongside regular rheumatology care and biologic therapy

---

14.15

Introduction to the use of, and monitoring of, biologic therapies for rheumatoid arthritis and consideration to the inclusion of foot pathologies

Dr Christopher Edwards, University Hospitals Southampton, Southampton

14.35

**Foot disease in the post-biologic era: is it mechanical or inflammatory?**

Dr Heidi Siddle, University of Leeds, Leeds

14.55

FeeTURA4: longitudinal evaluation of biologic therapies on rheumatoid arthritis foot pathology

Dr Lindsey Cherry, University of Southampton, Southampton

15.15

The ‘Rheumafoot’ multicentre parallel trial of podiatry care in rheumatoid arthritis: clinical study group (CSG) proposal update

Dr Gordon Hendry, Glasgow Caledonian University, Glasgow

15.35

Discussion

---

### British Health Professionals in Rheumatology osteoporosis special interest group

**Chair:** Ms Rachel Lewis, Cardiff University, Cardiff

**Aim:** To increase knowledge of management of acute vertebral fracture and common Fracture Liaison Services (FLS) questions

**Outcome 1:** Increased confidence in answering complex Fracture Liaison Services questions from patients

**Outcome 2:** To have a multi-disciplinary/holistic awareness for acute vertebral fracture management

**Outcome 3:** To have participated in peer discussion on case studies

14.15

Common and complex fracture liaison questions and discussion

Ms Cathy Churchman, United Bristol Healthcare Trust, Bristol

14.45

Acute vertebral fracture management the multidisciplinary team whole story

Dr Rachel Lewis, North Bristol NHS Trust, Bristol

---

**15.45 – 16.00 Tea and coffee**

This refreshment break is for those attending sessions scheduled at the end of the conference (16.00 – 17.30)
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>16.00 – 17.00</td>
<td><strong>British Society for Rheumatology NICE-accredited clinical guidelines</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Welcome and Introduction</strong></td>
</tr>
<tr>
<td></td>
<td>Dr Jo Ledingham, Chair of the Standards and Guidelines Working Group</td>
</tr>
<tr>
<td></td>
<td><strong>Guideline updates:</strong></td>
</tr>
<tr>
<td></td>
<td><strong>De-modifying anti-rheumatic drug (DMARD) use in rheumatoid arthritis</strong></td>
</tr>
<tr>
<td></td>
<td>Dr Tom Kennedy, Royal Liverpool University Hospital, Liverpool</td>
</tr>
<tr>
<td></td>
<td><strong>Management of polymyalgia rheumatica</strong></td>
</tr>
<tr>
<td></td>
<td>Prof Bhaskar Dasgupta, Southend University Hospital, Southend-on-Sea</td>
</tr>
<tr>
<td></td>
<td><strong>Gout management</strong></td>
</tr>
<tr>
<td></td>
<td>Prof George Nuki, University of Edinburgh, Edinburgh</td>
</tr>
<tr>
<td></td>
<td><strong>Question and answer session</strong></td>
</tr>
<tr>
<td>16.00 – 17.30</td>
<td><strong>Rheumatoid arthritis outcomes special interest group</strong></td>
</tr>
<tr>
<td></td>
<td>Chair: Dr Adam Young, City Hospital, St Albans</td>
</tr>
<tr>
<td></td>
<td><strong>Aim:</strong> Recent developments and reviews affecting the management of rheumatoid arthritis and its outcomes</td>
</tr>
<tr>
<td></td>
<td><strong>Outcome 1:</strong> Defining and developing a minimum core dataset for clinical trials and observational studies of rheumatoid arthritis</td>
</tr>
<tr>
<td></td>
<td><strong>Outcome 2:</strong> The importance, measurement and management of comorbidities in the management of rheumatoid arthritis</td>
</tr>
<tr>
<td></td>
<td><strong>Outcome 3:</strong> The level of knowledge and understanding of health economics that rheumatologist should be aware</td>
</tr>
<tr>
<td>16.00</td>
<td><strong>Development of a minimum core dataset in rheumatoid arthritis: a multidisciplinary exercise</strong></td>
</tr>
<tr>
<td></td>
<td>Dr Elena Nikiphorou, University College London, London</td>
</tr>
<tr>
<td>16.20</td>
<td><strong>How important is comorbidity in rheumatoid arthritis? Results from an Arthritis Research UK Clinical Study Group Work</strong></td>
</tr>
<tr>
<td></td>
<td>Dr Peter Dawes, Haywood Hospital, Stoke-on-Trent</td>
</tr>
<tr>
<td>16.40</td>
<td><strong>Should we be assessing fatigue in rheumatoid arthritis and if so, how?</strong></td>
</tr>
<tr>
<td></td>
<td>Prof Sarah Hewlett, University of the West of England, Bristol</td>
</tr>
<tr>
<td>17.00</td>
<td><strong>What rheumatologists need to know about health economics in management of rheumatoid arthritis</strong></td>
</tr>
<tr>
<td></td>
<td>Prof Alan Wailoo, the School of Health and Related Research (ScHARR), Sheffield and Dr Chris Deighton, President of the British Society for Rheumatology</td>
</tr>
<tr>
<td>17.20</td>
<td><strong>Discussion</strong></td>
</tr>
<tr>
<td>16.00 – 17.30</td>
<td><strong>Heritable disorders of connective tissue disease special interest group</strong></td>
</tr>
<tr>
<td></td>
<td>Chair: Prof Rodney Grahame, University College London, London</td>
</tr>
<tr>
<td></td>
<td><strong>Comprehensive care for hypermobility: filling in the gaps</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Experts, networks and commissioning</strong></td>
</tr>
<tr>
<td></td>
<td>• A national perspective</td>
</tr>
<tr>
<td></td>
<td>Dr Alan Hakim, London</td>
</tr>
<tr>
<td></td>
<td>• Local perspectives</td>
</tr>
<tr>
<td></td>
<td>Bill Ferrell, Glasgow</td>
</tr>
<tr>
<td>16.30</td>
<td><strong>Allied health professionals education and training</strong></td>
</tr>
<tr>
<td></td>
<td>Jane Simmonds, University of Hertfordshire, Hertfordshire</td>
</tr>
<tr>
<td>16.50</td>
<td><strong>Patient information and public awareness</strong></td>
</tr>
<tr>
<td></td>
<td>Donna Wicks, Hypermobility Syndromes Association (HMSA)</td>
</tr>
<tr>
<td>17.05</td>
<td><strong>Discussion</strong></td>
</tr>
</tbody>
</table>
The National Institute for Health and Care Excellence (NICE) is an independent organisation which provides authoritative and evidence-based guidance on the most effective ways to prevent, diagnose and treat disease and ill health.

Its accreditation programme helps health and social care professionals identify the most robustly produced guidance available, enabling them to deliver high quality care.

British Society for Rheumatology NICE accredited clinical guidelines

The British Society for Rheumatology guidelines gained NICE accreditation in February 2013, after a rigorous assessment of our guideline development process. BSR guidelines are permitted to include the NICE accreditation mark as a sign of quality assurance for the next five years.

BSR guidelines update

New guidelines - recently published:
• Vasculitis management

Expected shortly:
• Tocilizumab use in rheumatoid arthritis

Please join us at Rheumatology 2014 for a session on updates to our guidelines on Thursday 1 May at 16.00. The session will be chaired by Dr Jo Ledingham, Chair of the Standards and Guidelines Working Group, and provide updates on the following:

• DMARD use in rheumatoid arthritis:  
  Dr Tom Kennedy
• Management of polymyalgia rheumatica: 
  Prof Bhaskar Dasgupta
• Gout management: 
  Prof George Nuki

Do you have any suggestions for new evidence-based clinical practice guideline topics? Please let us know – we’d love to hear from you.

For more information, please see www.rheumatology.org.uk/guidelines
### British Health Professionals in Rheumatology rheumatoid arthritis special interest group

**Room 11C**

**Chair:** Ms Janet Cushnaghan, Hampshire Hospitals NHS Foundation Trust, Tadley

**Aim:** Delegates will participate in a session about various aspects of interest in rheumatoid arthritis

**Outcome 1:** Delegates will increase their knowledge of a treat to target approach in rheumatoid arthritis

**Outcome 2:** Delegates will gain an insight into patient preferences for route of administration of biologics

**Outcome 3:** Delegates will understand the issues around adherence with medication and how to improve

**16.00**

**Experiences of healthcare provision for foot ulceration in rheumatoid arthritis**  
Dr Jill Firth, University of Leeds, Leeds

**16.40**  
**Medication adherence in rheumatoid arthritis**  
Dr Kanta Kumar, University of Birmingham, Birmingham

### Vasculitis special interest group

**Room 11B**

**Chairs:** Dr David Carruthers, Sandwell & West Birmingham Hospitals, Birmingham; Prof Raashid Luqmani, University of Oxford, Oxford and Dr Chetan Mukhtyar, Norfolk and Norwich University Hospital, Norwich

**Aim:** To provide an update on current progress in epidemiology, trials, registries and clinical practice in the management of systemic vasculitis

**Outcome 1:** To understand how to measure disease activity and damage in systemic vasculitis using current clinical tools, to facilitate use of immunosuppressive therapies including biologics

**Outcome 2:** To understand the role of different therapies in the treatment of vasculitis in adults and children

**Outcome 3:** To understand the long term outcome, including mortality risk, co-morbidity, drug toxicity relapse and end stage organ disease in different forms of systemic vasculitis demiology and disease burden in systemic vasculitis

**16.00**  
**Epidemiology and disease burden in systemic vasculitis**  
Dr Richard Watts, Ipswich Hospital, Ipswich

**16.20**  
**Practical evaluation of systemic vasculitis: using the Birmingham Vasculitis Activity Score (BVAS) and Vasculitis Damage Index (VDI) in everyday management and in clinical studies**  
Prof Raashid Luqmani, University of Oxford, Oxford

**16.50**  
**Emerging studies in paediatric vasculitis**  
Dr Marinka Twilt, University of Birmingham, Birmingham

**17.10**  
**Getting involved in current studies and registries: how can I help?**  
Dr Neil Basu, University of Aberdeen, Aberdeen
Thursday 1 May  Special interest groups

### Musculoskeletal ultrasound special interest group

**Hall 1B**

**Chair:** Dr Ash Samanta, University Hospitals of Leicester NHS Trust, Leicester

**Aim:** To provide rheumatologists/Allied Health Professionals with an outline of changes in training resources available, how the British Society for Rheumatology’s training programmes are changing to take advantage of them, and offering advice how to tailor training to suit individual needs.

**Outcome 1:** Delegates will gain insight into the practical role ultrasound can have in helping understand anatomy and assessment.

**Outcome 2:** Delegates will be aware of the different ultrasound training resources and programmes that are available.

**Outcome 3:** Delegates will have a better understanding of how to access ultrasound training that is appropriate for their need.

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>16.00</td>
<td>Basic and functional anatomy</td>
</tr>
<tr>
<td></td>
<td>Dr Zunaid Karim, Pinderfields Hospital, Wakefield</td>
</tr>
<tr>
<td>16.25</td>
<td>Ultrasound training; what’s out there, and what’s changing?</td>
</tr>
<tr>
<td></td>
<td>Dr Cristina Estrach, Aintree University Hospital, Liverpool</td>
</tr>
<tr>
<td>16.50</td>
<td>Ultrasound training; what is best for you?</td>
</tr>
<tr>
<td></td>
<td>Dr Alison Hall, Keele University, Keele</td>
</tr>
<tr>
<td>17.15</td>
<td>Panel discussion, interactive with questions and answers</td>
</tr>
</tbody>
</table>

---

**HEBERDEN LIBRARY CATALOGUE**

**now available online**

The Heberden Library is an important collection of medico-historical books on rheumatism, gout and other allied conditions. It is maintained by the Royal College of Physicians on behalf of the British Society for Rheumatology and contains over 1,500 books, pamphlets and journals dating from 1534 to the present day.

The Heberden Library catalogue is now available to search online, and includes all the currently-catalogued books housed at Bride House and at the Royal College of Physicians.

Visit the British Society for Rheumatology’s website at www.rheumatology.org.uk for further information and to access the online catalogue.

---

Woodcut illustration of gout sufferers from Eyn verantwortung Podagrae vor dem Richter [Gout answers before the judge], published Mainz, 1537.